BridgeBio director granted RSUs and stock options

BridgeBio Pharma, Inc. director Ellis Andrea reported receiving new equity awards.

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. director Ellis Andrea reported receiving new equity awards. On June 22, 2026, Ellis was granted 3,990 restricted stock units that vest in full on June 22, 2027, subject to continued board service. Each RSU represents one share of common stock.

Ellis was also granted a stock option covering 5,277 shares of common stock at an exercise price of $68.92 per share, expiring on June 21, 2036, with all option shares vesting on June 22, 2027. Following these awards, Ellis directly holds 22,579 shares of common stock.

Insider Trade Summary

Grant/Award: 9,267 shares

Grant/Award 2 txns

Insider Ellis Andrea

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,277	$0.00	$0.00
Grant/Award	Common Stock	3,990	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,277 contracts (Direct); Common Stock — 22,579 shares (Direct)

Footnotes (3)

1. F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. F3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Key Figures

RSU grant size: 3,990 RSUs Option grant size: 5,277 shares Option exercise price: $68.92 per share +3 more

6 metrics

RSU grant size 3,990 RSUs Granted June 22, 2026; vest June 22, 2027

Option grant size 5,277 shares Stock option (right to buy) granted June 22, 2026

Option exercise price $68.92 per share Exercise price for 5,277-share stock option

Option expiration June 21, 2036 Expiration date of stock option

Common shares held 22,579 shares Total common stock directly held after transactions

Vesting date June 22, 2027 Full vesting date for RSUs and option shares

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), vest in full, contingent right, +1 more

5 terms

restricted stock units ("RSUs") financial

"Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest in full financial

"The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service"

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

exercise price financial

"conversion_or_exercise_price": "68.9200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did BridgeBio (BBIO) director Ellis Andrea receive?

Director Ellis Andrea received 3,990 restricted stock units and a stock option for 5,277 shares. Both awards were granted on June 22, 2026, as part of BridgeBio Pharma’s equity incentive compensation for board service.

When do Ellis Andrea’s BridgeBio (BBIO) RSUs and options vest?

Both the 3,990 RSUs and the option for 5,277 underlying shares vest in full on June 22, 2027. Vesting is contingent on Ellis Andrea’s continued service on BridgeBio Pharma’s board of directors through that date.

What is the exercise price and expiration date of Ellis Andrea’s BridgeBio option?

The stock option granted to Ellis Andrea has an exercise price of $68.92 per share and expires on June 21, 2036. It covers 5,277 underlying common shares, which all vest together on June 22, 2027.

How many BridgeBio (BBIO) shares does Ellis Andrea hold after these grants?

After the reported grants, Ellis Andrea directly holds 22,579 shares of BridgeBio common stock. This figure reflects holdings following the June 22, 2026 equity awards, excluding the unexercised option shares that may be acquired in the future.

What do the BridgeBio RSUs granted to Ellis Andrea represent?

Each restricted stock unit granted to Ellis Andrea represents a contingent right to receive one share of BridgeBio common stock. The 3,990 RSUs will settle into shares once they vest on June 22, 2027, assuming continued service on the board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 06:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ellis Andrea

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		A(1)		3,990	A	$0(2)	22,579	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$68.92	06/22/2026		A		5,277		(3)	06/21/2036	Common Stock	5,277	$0	5,277	D

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)